{
    "organizations": [],
    "uuid": "5b4a944e5a67f0f7dd5f44274a8ab889dc5cfdd9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-actinium-pharmaceuticals-announces/brief-actinium-pharmaceuticals-announces-activation-of-16th-clinical-trial-site-idUSASB0C7ON",
    "ord_in_thread": 0,
    "title": "BRIEF-Actinium Pharmaceuticals Announces Activation Of 16th Clinical Trial Site",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Actinium Pharmaceuticals Inc:\n* ACTINIUM PHARMACEUTICALS ANNOUNCES ACTIVATION OF SIXTEENTH CLINICAL TRIAL SITE IN THE PIVOTAL PHASE 3 SIERRA TRIAL FOR IOMAB-B\n* ACTINIUM PHARMACEUTICALS INC - ACTIVATED SIXTEEN CLINICAL TRIAL SITES IN PHASE 3 SIERRA TRIAL​\n* ACTINIUM PHARMACEUTICALS INC - ‍EXPECTS TO PROVIDE UPDATES ON IOMAB-B SIERRA TRIAL IN LINE WITH PREVIOUSLY STATED OBJECTIVES FOR 2018 AND 2019​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T20:49:00.000+02:00",
    "crawled": "2018-02-28T13:00:40.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "actinium",
        "pharmaceutical",
        "inc",
        "actinium",
        "pharmaceutical",
        "announces",
        "activation",
        "sixteenth",
        "clinical",
        "trial",
        "site",
        "pivotal",
        "phase",
        "sierra",
        "trial",
        "actinium",
        "pharmaceutical",
        "inc",
        "activated",
        "sixteen",
        "clinical",
        "trial",
        "site",
        "phase",
        "sierra",
        "actinium",
        "pharmaceutical",
        "inc",
        "provide",
        "update",
        "sierra",
        "trial",
        "line",
        "previously",
        "stated",
        "objective",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}